Andrew Dickinson Sells 3,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock

18 Jun 2026, 09:44 by Mitch Edgeman · The Markets Daily

Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report) CFO Andrew Dickinson sold 3,000 shares of the company’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $125.40, for a total value of $376,200.00. Following the sale, the chief financial officer owned 171,646 shares of the company’s stock, valued at approximately $21,524,408.40. The trade was a 1.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Gilead Sciences Trading Down 1.4%

GILD stock opened at $125.45 on Thursday. The company has a market cap of $155.75 billion, a price-to-earnings ratio of 17.09 and a beta of 0.31. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. The business has a fifty day simple moving average of $132.31 and a 200-day simple moving average of $134.30. Gilead Sciences, Inc. has a 52 week low of $104.46 and a 52 week high of $157.29.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. The business had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The business’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same period in the prior year, the firm posted $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, equities research analysts expect that Gilead Sciences, Inc. will post -0.8 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be issued a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 2.6%. The ex-dividend date is Monday, June 15th. Gilead Sciences’s dividend payout ratio is currently 44.69%.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

Positive Sentiment: The FDA accepted Gilead’s filing for once-weekly oral Yeztugo for HIV prevention, a key step that could expand the company’s long-acting PrEP franchise and create a new growth opportunity if approved. FDA Accepts Gilead’s Filing for Weekly Oral Yeztugo for HIV Prevention
Positive Sentiment: Cantor Fitzgerald reaffirmed its Overweight rating and set a $155 price target, indicating analyst confidence in upside from current levels. Benzinga report on Cantor Fitzgerald rating
Positive Sentiment: Gilead donated more than 2,000 vials of remdesivir to Uganda to support Ebola response efforts, which may help reinforce the company’s public-health profile, though the direct financial impact appears limited. Gilead Sciences Donates Remdesivir to Uganda
Neutral Sentiment: Two senior insiders, including CFO Andrew D. Dickinson and executive Johanna Mercier, sold shares under pre-arranged 10b5-1 plans. These sales are routine and not necessarily a bearish signal, but they can still pressure sentiment. SEC filing for Andrew D. Dickinson sale SEC filing for Johanna Mercier sale
Neutral Sentiment: The stock had recently been under mild pressure and is still trading below key moving averages, so the latest move looks more like a reaction to the mixed news flow than a change in fundamentals. Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on GILD. Weiss Ratings downgraded Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, May 28th. Jefferies Financial Group began coverage on Gilead Sciences in a report on Tuesday, March 10th. They issued a “buy” rating and a $180.00 price target for the company. Argus increased their price target on Gilead Sciences from $135.00 to $165.00 and gave the company a “buy” rating in a report on Thursday, February 19th. Leerink Partners lowered their price target on Gilead Sciences from $148.00 to $146.00 in a report on Friday, May 8th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $155.00 price target on shares of Gilead Sciences in a report on Tuesday. Twenty-five research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $158.41.

Check Out Our Latest Report on Gilead Sciences

Hedge Funds Weigh In On Gilead Sciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Strategic Investment Solutions Inc. IL purchased a new position in Gilead Sciences in the 4th quarter valued at about $25,000. Vermillion & White Wealth Management Group LLC boosted its position in Gilead Sciences by 71.4% in the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 85 shares during the last quarter. Quattro Advisors LLC purchased a new position in Gilead Sciences in the 4th quarter valued at about $26,000. Wealth Preservation Advisors LLC boosted its position in Gilead Sciences by 60.0% in the 4th quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 81 shares during the last quarter. Finally, Wilkerson Advisory Group LLC boosted its position in Gilead Sciences by 54.2% in the 1st quarter. Wilkerson Advisory Group LLC now owns 222 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 78 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Company Profile

(Get Free Report)

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.